Why Turing Pharmaceuticals CEO Martin Shkreli Still Hasn’t Cut The Cost of Daraprim
Activists hold signs containing the image of Turing Pharmaceuticals CEO Martin Shkreli in front of Turing’s offices in New York on Oct. 1, 2015, during a protest. (Image via AP Photo/Craig Ruttle)
As of a week ago, pharmaceuticals purveyor Martin Shkreli hadn’t kept his promise to lower the cost of a toxoplasmosis drug after outcry over its 5,000% price hike over the summer. Nothing much has changed since—except now the Turing Pharmaceuticals CEO is explaining why Daraprim is still boasting exorbitant prices.
Related: Here’s How Price-Gouging Drug CEO Says He Sleeps at Night
“I said that it would take a long amount of time to figure out how and when to lower the price,” Shkreli tells Business Insider, ostensibly referencing what he told ABC News last month about lowering the price (though he didn’t appear to mention any timeframe). What’s holding things up, per Shkreli: the assessment process to find a pricing/demand sweet spot to bring the price per pill down from the current $750. “Until we figure out demand, we won’t lower the price,” he tells BI. “We have to find a safe price to lower it to.”
Related: Something Weird Is Happening With Placebos in America
Shkreli does add, however, that the new price won’t be close to the original $13.50 per pill. He also takes umbrage at getting flak for doing what other companies, such as Pfizer and Merck, do. “There have been hundreds of companies that have raised [their drug prices] higher, and they’re not rolling back their prices, so why should we?” Shkreli points out.
Related: 7 Celebs Who’ve Revealed Surprising Health Conditions
Meanwhile, New York’s AG has started an inquiry into Turing, also involving whether the company violated antitrust laws by restricting Daraprim distribution to thwart generic competitors, the New York Times reports. By significantly cutting where competitors can pick up Daraprim, Turing can ensure they have a hard time testing those samples to produce an alternative drug, the paper explains. A letter from the AG’s office, seen by the Times and sent to Turing on Monday, tells the company to get in touch and to “retain all documents that are potentially relevant to this inquiry.” (Some think we should thank Shkreli.)
By Jenn Gidman
More From Newser:
Study: Your Butt Doesn’t Make You Attractive
Your Earwax Says a Lot About You
This article originally appeared on Newser: Why CEO Hasn’t Cut Drug’s 5K% Price Hike
